









Markets
/
Stocks
/
nasdaq-roiv
/

Roivant Sciences Ltd

ROIV

15.040USD

-0.050-0.33%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

10.26BMarket Cap

LossP/E TTM



Roivant Sciences Ltd

15.040

-0.050-0.33%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

35 / 175

Overall Ranking

130 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

19.650

Target Price

+30.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 29.05M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 171.98M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -21.64, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 776.63M shares, decreasing 15.95% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 39.25M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.15.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.20, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.17M, representing a year-over-year decrease of 96.06%, while its net profit experienced a year-over-year decrease of 334.38%.

Score

Industry at a Glance

Previous score

6.20

Change



Financials

8.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.26

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.13

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -21.71, which is -108.21% below the recent high of 1.78 and 61.21% above the recent low of -8.42.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 35/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Roivant Sciences Ltd is 20.00, with a high of 24.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

19.650

Target Price

+30.22%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Roivant Sciences Ltd

ROIV

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.29, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 16.91 and the support level at 12.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.29

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.397

Buy

RSI(14)

76.957

Buy

STOCH(KDJ)(9,3,3)

72.373

Neutral

ATR(14)

0.589

High Vlolatility

CCI(14)

97.784

Neutral

Williams %R

24.574

Buy

TRIX(12,20)

0.975

Sell

StochRSI(14)

42.544

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

14.708

Buy

MA10

14.219

Buy

MA20

13.196

Buy

MA50

12.205

Buy

MA100

11.676

Buy

MA200

11.299

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 112.42%, representing a quarter-over-quarter decrease of 1.07%. The largest institutional shareholder is The Vanguard, holding a total of 39.25M shares, representing 5.75% of shares outstanding, with 4.92% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Dexcel Pharma Technologies, Ltd.

102.85M

SB Investment Advisers (UK) Limited

61.85M

-0.33%

Fidelity Management & Research Company LLC

51.67M

+4.80%

Ramaswamy (Vivek)

50.64M

-3.60%

The Vanguard Group, Inc.

Star Investors

40.68M

-7.54%

BlackRock Institutional Trust Company, N.A.

37.01M

-1.24%

Viking Global Investors LP

Star Investors

46.01M

-3.76%

Morgan Stanley Investment Management Inc. (US)

31.00M

+2.42%

QVT Financial LP

65.79M

Rubric Capital Management LP

17.77M

-11.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.37, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.